Document is current
Any future updates will be listed below
-
Authors
Garces, Kimberly N.
Cocores, Alexandra N.
Goadsby, Peter J.
Monteith, Teshamae S. https://orcid.org/0000-0001-8912-252X
- License Information
-
More Information
Article History
Accepted: 14 October 2022
First Online: 23 November 2022
Declarations
:
: Kimberly Garces and Alexandra Cocores do not report any significant disclosures or conflicts of interest. Peter James Goadsby reports, over the last 36 months, grants and personal fees from Eli-Lilly and Company, grant from Celgene, and personal fees from Aeon Biopharma, Allergan/Abbvie, Amgen, Biodelivery Sciences International, Biohaven Pharmaceuticals Inc., CoolTech LLC, Dr Reddys, Epalex, GlaxoSmithKline, Impel Neuropharma, Lundbeck, Novartis, Praxis, Sanofi, Satsuma and Teva Pharmaceuticals, and personal fees for advice through Gerson Lehrman Group, Guidepoint, SAI Med Partners, Vector Metric, and fees for educational materials from CME Outfitters, Omnia Education, WebMD, and publishing royalties or fees from Massachusetts Medical Society, Oxford University Press, UptoDate and Wolters Kluwer, and for medicolegal advice in headache. Teshamae Monteith has received personal compensation for serving on advisory boards for Biohaven, Allegan/Abbvie, Lundbeck, Amgen, Teva, Linpharma and Impel Neuropharmaceuticals. She has also served as a site principal investigator without direct compensation for Teva, Eli Lilly, Electrocore, Amgen, Novartis.
